The Centers for Medicare and Medicaid Services has awarded RELI Group a 5-year, $60 million contract to support monitoring, oversight, compliance and auditing for the Medicare Drug Price Negotiation Program.
RELI Group won the contract from a pool of seven proposals. It adds to the company’s portfolio of over 20 active CMS contracts.
RELI Group founder and CEO Mohammad Elias said the company is honored to support CMS in its efforts to improve transparency and accountability in Medicare drug pricing.
“At RELI Group, we are deeply committed to advancing CMS’ mission through innovative oversight, compliance, and auditing solutions that strengthen public trust and deliver real impact,” he added. “We look forward to continuing our partnership with CMS to ensure the success of the Medicare Drug Price Negotiation Program.”
RELI Group’s team includes medical directors, physicians, nurses, coders and quality specialists. The company also supports other CMS programs, including RVC, AMS, ASIC, MRAC and CSMM.
Work on the new contract begins May 2.